Category: Debates & Comparisons
Three traditional calming herbs share the same shelf and the same weak evidence problem, but not equally. Here is the honest breakdown of valerian, passionflower and hops for sleep, including why hops almost never gets studied alone.
Category: Debates and Comparisons | Reading time: ~13 min | Level: Intermediate
Pick up almost any "natural sleep aid" from a UK chemist or a US health shop and the label reads like a small committee decided together: valerian root, passionflower, hops, sometimes all three in one capsule alongside chamomile or lemon balm for good measure. The implicit message is that more traditional calming herbs equals more sleep help. What the label does not say, because labels never do, is that these three herbs are not remotely equal in how well they have actually been studied, and one of them has barely been studied on its own at all.
That last fact surprised even the people who wrote Europe's official herbal monograph on hops. When regulators sat down to review the clinical trial evidence for hops and sleep, they found that nearly every study tested hops mixed with valerian, never hops by itself, and concluded honestly that no firm verdict on hops alone could be reached. That is a genuinely useful thing to know before buying a product built around the assumption that hops is doing independent work.
So this is not a simple ranking exercise. It is three herbs with three different evidence shapes: one heavily studied and still disappointing on the measures that matter most, one thinner but with a recent objective result worth paying attention to, and one that mostly exists in the literature as somebody else's plus-one. Here is what each has actually earned, and which one deserves your money first.
Valerian is the root and rhizome of Valeriana officinalis, a tall flowering plant whose underground parts carry valerenic acid, the compound most associated with its effects. It is the oldest and most clinically studied of the three, with a reputation as a sleep and nerve herb running back centuries.
Passionflower is the aerial parts, leaves, stems and flowers, of Passiflora incarnata, a climbing vine native to the Americas, traditionally used for restlessness and nervous tension with a lighter reputation than valerian.
Hops is the female flower, or strobile, of Humulus lupulus, the same plant used to bitter and flavour beer. Its sedative reputation is old enough to have a folk explanation (hop pickers reportedly grew drowsy at work), and its proposed active compounds include bitter acids and the flavonoid 8-prenylnaringenin.
All three share a proposed mechanism: mild action on the brain's GABA system, the calming pathway that several conventional sedatives also target. That shared mechanism is why they end up in the same capsule, aimed at the same complaint, a mind that will not settle at bedtime. Where they diverge sharply is in how much good evidence backs that shared promise up.
Valerian has the strongest regulatory footing of the three by a wide margin. Europe's herbal monograph grants it well established use status for the relief of mild nervous tension and sleep disorders, a genuinely higher rung than the traditional-use registration passionflower and hops hold [3]. That status draws on long-standing use and older literature rather than a body of modern high-quality trials, and the monograph is honest that its own posology reflects that: valerian is explicitly "not suitable for acute interventional treatment," with continued use over two to four weeks recommended for an optimal effect [3].
Read the modern trial evidence and the picture turns unflattering fast. The most authoritative synthesis available, a 2024 umbrella review of eight systematic reviews drawn from 70 screened records, concluded plainly that "the results showed no evidence of efficacy for the treatment of insomnia" [1]. The same review found valerian "appears to be effective concerning subjective improvement of sleep quality," while stating that effectiveness "has not been demonstrated with quantitative or objective measurements" [1]. An older, frequently cited meta-analysis of 16 trials in over a thousand people did find people were more likely to report improved sleep, but the authors themselves flagged clear evidence of publication bias in that result and noted significant methodological problems across most of the pooled studies [2]. The American Academy of Sleep Medicine has gone further still, explicitly recommending against valerian for chronic insomnia in its 2017 clinical practice guideline, a position NCCIH's own summary repeats [4].
The recurring signature across valerian's literature is the same one that shows up for chamomile and lemon balm: subjective sleep quality sometimes moves, objective sleep essentially never does [1]. That is the fingerprint of ritual and expectation more than pharmacology. Valerian's genuine strength lies elsewhere, in safety and tolerability across a very large pooled population, not in proven potency [1].
Honest grade: weak for insomnia specifically, despite being the best-researched and most regulator-endorsed herb of the three. The reputation is doing more work than the data.
Safety-wise, valerian's tolerability record is strong, though it carries one signal worth knowing. NIH's LiverTox database rates it a probable, rare cause of liver injury, a step above chamomile and lavender's clean rating, but that signal attaches mainly to products combining valerian with other botanicals such as skullcap or black cohosh, and cases remain very rare overall [5]. Reported side effects are mostly mild: headache, stomach upset, mental dullness and vivid dreams, with withdrawal-type symptoms possible after abrupt discontinuation following long regular use [4].
Passionflower's regulatory position is a rung below valerian's. It holds a European traditional-use registration only, for relief of mild symptoms of mental stress and to aid sleep, the same long-standing-use basis chamomile and lemon balm hold [8]. In plain terms, the regulator recognises passionflower as a traditionally used calming herb, not a clinically demonstrated one.
The early trial evidence is small and largely subjective. A double-blind, placebo-controlled crossover trial in 41 people gave passionflower herbal tea for one week and found a small improvement in self-reported sleep quality compared with placebo tea [6]. That is a real, published, controlled result, but it measures perception rather than instrument-verified sleep, and the sample and duration were both modest.
The more recent and better-designed trial changes the picture somewhat. A 2020 double-blind, randomised, placebo-controlled study in 110 adults meeting formal diagnostic criteria for insomnia disorder tested a passionflower extract against placebo for two weeks, using polysomnography, an overnight instrument-based sleep study, rather than a questionnaire [7]. Total sleep time increased significantly more in the passionflower group than placebo, and sleep efficiency and time spent awake after falling asleep both improved within the passionflower group, though those two measures did not reach statistical significance against placebo directly [7]. That is a genuinely more objective signal than anything currently available for hops, and arguably more specific than valerian's own recent umbrella-review verdict, though it remains a single trial that has not yet been replicated or pooled into a wider synthesis.
Honest grade: limited, thinner and smaller in volume than valerian's evidence base, but with one recent, better-controlled, objectively measured trial that deserves more attention than passionflower usually gets in comparison articles that treat it purely as "the gentle one."
Passionflower's safety record is generally good, with drowsiness and occasional dizziness the main reported effects, though it has less long-term human safety data behind it than valerian [8]. Like the other two herbs here, it may add to the effect of sedatives and alcohol, and safety in pregnancy and breastfeeding has not been adequately established.
Hops occupies an unusual position in this comparison, because the honest evidence summary is mostly about what has not been studied rather than what has. Europe's herbal monograph does grant hops a traditional-use registration for relief of mild symptoms of mental stress and to aid sleep, based on long-standing use in tea, powdered form and alcoholic extracts across Europe [11]. But when the regulator's own assessment turned to the clinical trial evidence, it found that essentially every relevant study tested hops combined with valerian root, never hops on its own, and concluded that "firm conclusions on the effects of hop strobile could not be drawn" as a result [11].
That gap shapes everything else in this section. The best-known trial involving hops is a 184-person, multicentre, randomised, placebo-controlled trial comparing a valerian-hops combination and diphenhydramine (a sedating antihistamine) against placebo over 28 days. It found modest improvements in subjective sleep parameters with both active treatments, but few individual comparisons against placebo reached statistical significance [9]. A separate, smaller polysomnography-based trial of a different fixed valerian-hops extract found the combination performed better than placebo on some sleep measures in people with non-organic insomnia [10]. Both of these are valerian-hops trials. Neither isolates what hops itself is contributing, if anything, versus what valerian is contributing, if anything.
Honest grade: not separately gradeable with confidence. Hops has a traditional-use registration and a plausible GABA-related mechanism in laboratory work, but essentially no solo human clinical trial evidence exists to grade on its own terms. Its reputation as a sleep herb has been built almost entirely through its long partnership with valerian, in tradition and in trial design alike.
Safety at typical doses is generally good, but one point deserves honest mention rather than omission: hops contains 8-prenylnaringenin, considered one of the most potent plant-derived oestrogen-like compounds identified in any botanical [12]. Regulatory assessment notes that the concentrations reached through ordinary hop supplement or tea doses sit well below the levels studied for hormonal effects, but the compound's existence is a legitimate reason for caution in people with hormone-sensitive conditions, and it is worth knowing about rather than discovering after the fact [12]. As with valerian and passionflower, solo long-term human safety data for hops is thinner than either of the other two.
| Feature | Valerian | Passionflower | Hops | |---|---|---|---| | Plant part | Root and rhizome | Aerial parts (leaf, stem, flower) | Female flower (strobile) | | European status | Well established use (nervous tension, sleep) [3] | Traditional use (mental stress, sleep) [8] | Traditional use (mental stress, sleep) [11] | | Best synthesis verdict | No proof of efficacy for insomnia [1] | No pooled synthesis; one PSG trial found increased total sleep time [7] | Regulator: no firm conclusion possible, virtually all trials combine it with valerian [11] | | Usual study design | Solo trials, decades of research | Solo and combination trials | Almost exclusively combination trials with valerian [9][10] | | Evidence grade | Weak, for insomnia specifically | Limited, thinner than valerian, one encouraging objective result | Not separately gradeable; evidence is combination-only | | Onset | Gradual, judged over 2 to 4 weeks [3] | Not established; used as a calming ritual | Not established; used as a calming ritual | | Typical feel | Heavier, more sedative; can cause vivid dreams | Lighter, gentler; less sedating | Mild; rarely used alone in practice | | Key safety flag | Rare liver signal in combination products [5] | Good tolerability; less long-term data | 8-prenylnaringenin, an oestrogenic compound, at typically low exposure [12] |
The pattern across the row for "usual study design" is the single most important line in this table. Valerian and passionflower have each, at least sometimes, been tested as the only active ingredient. Hops effectively never has. That is not a criticism of hops as a plant; it is a statement about a genuine hole in the human research record that every seller of a hops-containing product should be honest about.
Start by naming the problem the way the researchers did. If you are struggling with sleep onset, a mind that will not switch off, valerian and passionflower both have at least some direct trial evidence aimed at exactly that. If you are struggling with staying asleep or waking frequently, passionflower's 2020 polysomnography trial is currently the most specific piece of objective evidence among the three for that particular pattern [7].
Second, treat valerian's regulatory status and passionflower's newer trial as two different kinds of evidence, not directly comparable ones. Valerian's well established use status reflects decades of accumulated traditional and older-literature evidence rather than proof from a modern trial. Passionflower's 2020 result is a single, well-designed modern trial that has not yet been replicated. Neither is definitive; they are simply different flavours of "promising but not proven."
Third, be realistic about hops specifically. If a sleep product's marketing leans heavily on hops as an active driver of the effect, treat that claim with more scepticism than the same claim made about valerian or passionflower, because the regulatory and clinical record genuinely cannot support attributing an independent effect to hops with any confidence. That does not make hops useless in a combination product; it means its individual contribution is currently unknowable.
Fourth, set expectations on timing across all three. None of them is a same-night solution. Valerian's own monograph states it is not suitable for acute treatment, and the trial evidence for passionflower and hops-valerian combinations generally runs one to four weeks before an effect is assessed. Judge any of these over a genuine trial period, not a single restless evening.
Valerian is the sensible default first trial, not because its evidence is strong, but because it is the deepest, the most regulator-endorsed, and the most extensively safety-tested of the three. If you want the option with the longest track record and are prepared for a modest, mostly subjective effect, start there [1][3].
Passionflower is the better choice if valerian's heaviness, smell or vivid dreams put you off, or if your main complaint is staying asleep rather than falling asleep. Its evidence base is smaller, but its most recent trial is arguably more rigorous on the specific outcome that matters, objectively measured sleep, than anything currently available for the other two [7].
Hops is best understood as valerian's traditional partner rather than a solo contender. If you are drawn to a valerian-hops combination product, you are trying something with a real, if modest, evidence base behind the pairing [9][10]. If you are buying a hops-only product expecting it to work the way valerian or passionflower might, you are relying on tradition and laboratory mechanism rather than any solo human trial, and you should know that going in.
All three herbs are generally well tolerated by healthy adults at sensible doses, and none is consequence-free.
Valerian has an excellent overall tolerability record, with side effects usually limited to mild headache, stomach upset, mental dullness or vivid dreams [4]. It carries a rare liver signal attached mainly to multi-herb combination products rather than valerian alone [5]. It should not be combined with alcohol or sedatives, may impair driving, is not recommended under 12, and its safety in pregnancy and breastfeeding has not been established [3][4]. Stopping it abruptly after long regular use may cause withdrawal-type symptoms such as anxiety and restlessness [4].
Passionflower is likewise generally well tolerated, with drowsiness and occasional dizziness the main reported effects, but with less long-term safety data behind it than valerian [8]. It may add to the effect of sedatives and alcohol, may impair driving, and is not recommended in pregnancy or breastfeeding for want of adequate data.
Hops is generally well tolerated at typical doses. Its most distinctive caution is 8-prenylnaringenin, an oestrogen-like compound; ordinary supplement exposure appears to sit below levels studied for hormonal effects, but anyone with a hormone-sensitive condition should discuss it with a clinician rather than assume it is irrelevant [12]. Solo long-term human safety data for hops is the thinnest of the three, since almost all trial exposure has come through combination products.
For all three, the same rule applies: do not stack any of them on top of a prescription sedative, sleep medicine, antidepressant or alcohol on your own initiative, since layering calming agents can leave you impaired in ways a single mild herb would not.
Pregnant, breastfeeding, or on medication? Check with a healthcare professional first.
We would rather tell you which of these three has the thinnest evidence than let a combination product's label imply all three are pulling equal weight, because that is the more useful, and more honest, thing to know before you spend money.
If your pattern is a wired mind at an otherwise normal bedtime, a calming evening ritual is where a mild herb earns its modest keep, and our chamomile sleep tea is built in that same spirit: a warm drink and a consistent cue that the day is done, described with the same care we have used throughout this comparison. We are not picking a side between valerian, passionflower and hops here, because the honest answer depends on which problem you actually have and how you tolerate each herb, not on which one we would prefer to sell you.
For the deeper mechanics behind the shared GABA story, or a closer look at valerian and passionflower head to head, our companion comparisons and the wider Remedy Library are written in the same register: name the grade, show the study, match the tool to the problem.
1. Valente V, et al. (2024). Efficacy and safety of valerian for insomnia: an umbrella review of systematic reviews. European Neuropsychopharmacology. PMID 38359657. No evidence of efficacy for insomnia; subjective sleep quality sometimes improves, objective measures do not. 2. Bent S, et al. (2006). Valerian for sleep: a systematic review and meta-analysis, 16 trials, n=1,093. American Journal of Medicine. PMID 17145239. Reported improved subjective sleep but flagged publication bias and methodological problems. 3. European Medicines Agency, Committee on Herbal Medicinal Products (2016). European Union herbal monograph on Valeriana officinalis L., radix (EMA/HMPC/150848/2015, Corr.1). Well established use status; not suitable for acute treatment; judged over two to four weeks. 4. National Center for Complementary and Integrative Health (2023). Valerian. Government evidence synthesis; describes valerian sleep evidence as inconsistent, cites the 2017 AASM guideline recommending against valerian for chronic insomnia, and lists safety cautions. 5. National Institutes of Health, LiverTox (2020). Valerian, likelihood score C. Government evidence database entry; probable rare cause of liver injury, mainly in combination products. NBK548255. 6. Ngan A, Conduit R (2011). A double-blind, placebo-controlled investigation of the effects of Passiflora incarnata (passionflower) herbal tea on subjective sleep quality. Phytotherapy Research. PMID 21294203. Small improvement in self-reported sleep quality over one week, n=41. 7. Lee J, et al. (2020). Effects of Passiflora incarnata Linnaeus on polysomnographic sleep parameters in subjects with insomnia disorder: a double-blind randomized placebo-controlled study. International Clinical Psychopharmacology. PMID 31714321. n=110; significant increase in total sleep time versus placebo after two weeks. 8. European Medicines Agency, Committee on Herbal Medicinal Products (2014). European Union herbal monograph on Passiflora incarnata L., herba. Traditional-use registration for mild symptoms of mental stress and to aid sleep. 9. Morin CM, Koetter U, Bastien C, Ware JC, Wooten V (2005). Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep. PMID 16335333. n=184; modest subjective improvements with active treatments, few comparisons statistically significant versus placebo. 10. Koetter U, Schrader E, Kaufeler R, Brattstrom A (2007). A fixed valerian-hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. Phytotherapy Research. PMID 17486686. Randomised, double-blind, placebo-controlled trial with polysomnography; combination outperformed placebo on some sleep measures. 11. European Medicines Agency, Committee on Herbal Medicinal Products (2016). European Union herbal monograph on Humulus lupulus L., flos. Traditional-use registration; notes that clinical studies used hop-valerian combinations only, so firm conclusions on hops alone could not be drawn. 12. European Medicines Agency, Committee on Herbal Medicinal Products (2018). Assessment report on Humulus lupulus L., flos, revision 1. Discusses 8-prenylnaringenin as a potent phytoestrogen and typical supplement exposure relative to hormonally active levels.
Valerian has the deepest research base and the strongest European regulatory footing, but its own most authoritative synthesis, a 2024 umbrella review, found no evidence it actually works for insomnia on objective measures. Passionflower has fewer trials but one recent one used polysomnography and found a real increase in total sleep time. Hops has almost no solo evidence at all; nearly every trial studies it combined with valerian. If pressed to name one, valerian is still the reasonable default to trial first, on the understanding that "reasonable default" is a modest claim, not a guarantee.
Traditional and commercial sleep blends often combine two or all three, most commonly valerian with hops, on the theory that mild calming herbs complement each other. The valerian-hops combination has the most trial support of any pairing here, though the results are modest. There is no strong evidence that stacking all three outperforms one alone, and combining sedating agents raises the risk of next-day grogginess, so more is not automatically better.
Partly tradition, partly a gap in the evidence. Europe's herbal regulator reviewed the clinical literature on hops for sleep and found that essentially every trial tested hops combined with valerian, not hops alone, so no firm conclusion could be drawn about hops by itself. Manufacturers have followed the same pattern the research followed, which means hops has built a reputation as a sleep herb largely through association rather than through its own solo trials.
The evidence is limited but more encouraging on objective measures than valerian's. An early trial using passionflower tea found a small improvement in self-reported sleep quality over a week. A more recent and better-designed trial used polysomnography, the gold standard for measuring sleep, in 110 adults with diagnosed insomnia disorder, and found a significant increase in total sleep time after two weeks versus placebo. That is a genuinely interesting, if still preliminary, signal.
None of the three is a same-night sleeping pill, and treating them that way is the most common reason people give up on them early. Valerian's own European monograph states it is not suitable for acute treatment and recommends continued use over two to four weeks. Passionflower and hops trials generally run one to two weeks before measuring an effect. Give any of these a genuine, consistent trial rather than judging on the first evening.
Generally yes at food and supplement doses, with one specific point worth knowing: hops contains 8-prenylnaringenin, one of the most potent plant oestrogen-like compounds identified, though the concentrations reached through normal supplement use are far below the levels studied for hormonal effects. Most human sleep research has only tested hops in combination with valerian, so solo long-term human safety data is thin. As with the other two herbs, avoid combining with alcohol or sedatives without medical advice.
Valerian has the most tolerability data behind it, drawn from thousands of trial participants, but it also carries a rare liver signal attached mainly to combination products. Passionflower has a good tolerability record with less long-term data. Hops is generally well tolerated but its solo human safety data is the thinnest of the three, and its oestrogenic compound is worth knowing about even though typical doses are unlikely to reach hormonally active levels.
They solve a different problem. Melatonin is a body-clock signal, best evidenced for timing issues such as jet lag or shift work. Valerian, passionflower and hops are calming herbs aimed at a wired mind at a normal bedtime. If your issue is arousal rather than timing, a calming herb is the more logical category to try, though none of the three has evidence as strong as melatonin's for its own best-proven use.
Passionflower is the more sensible next step. It has a lighter, less heavy-sedating reputation than valerian and is not particularly associated with vivid dreams. Its evidence is thinner than valerian's, so treat it as a genuine experiment rather than a guaranteed upgrade, but if valerian's side effects outweighed a weak benefit for you, switching to a gentler herb with different drawbacks is reasonable. Give it two weeks of consistent evening use before judging it.
The honest answer is unclear but plausible. A large 184-person trial found modest improvements in subjective sleep with the combination, though few comparisons against placebo reached statistical significance, and Europe's regulator has said hops alone cannot be judged because it has almost never been tested without valerian. The combination is not proven superior to valerian by itself, but it has a long tradition and a reasonable safety record, so it is not an unreasonable thing to try.
Passionflower is generally regarded as the lightest of the three, less associated with the heavy, dulled feeling some people report with valerian. That said, gentleness is a reputation more than a rigorously measured property, since passionflower's trial base is smaller than valerian's. Start with the lowest labelled dose, use it consistently for a week or two, and stop if you notice any daytime grogginess, since individual sensitivity varies more than the marketing suggests.
The most relevant data point is passionflower's 2020 polysomnography trial, which found an increase in total sleep time and improvements in sleep efficiency and time spent awake after initially falling asleep, in adults with diagnosed insomnia disorder. That is one trial, not a settled answer, but it is currently the most specific objective evidence among these three herbs for a staying-asleep problem rather than a falling-asleep one. Track your actual nights for two weeks before deciding it is working.